President Donald Trump is set to speak today on how Tylenol may be linked to autism. Here's when, who makes Tylenol, and about the NJ company Kenvue.

Economists saw “limited” risk to the pharmaceutical firm’s stock, despite some expected impact on Tylenol consumption.

Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.

Tylenol, a popular over-the-counter pain reliever whose active ingredient is acetaminophen, is made by Kenvue, a spinoff of Johnson & Johnson. In early spring, the company moved its global headquarters to New Jersey, cutting the ribbon on the new location with Gov. Phil Murphy and then-Kenvue CEO Thibaut Mongon.

“Don’t take Tylenol,” Trump instructed pregnant women around a dozen times during a White House news conference. He also urged mothers not to give infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in other countries.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.

Kenvue stock pares losses after Trump claims about Tylenol's link to autism. Citi analysts said there was a lack of new scientific evidence to support it.

Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it.

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consider President Donald Trump's new advice that pregnant women avoid the pain killer as it decides whether to revive their lawsuits.

Shares may be rising because investors expected the White House to announce stricter regulations on the medication, Citi analysts said.

Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.